Diligence memo · auto-generated · as of July 2, 2026
Taligen Therapeutics Inc
Taligen Therapeutics Inc looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Taligen Therapeutics Inc operates in Biotechnology, based in CAMBRIDGE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Taligen Therapeutics Inc has raised $62M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $36M on 2008-01-03.
Most recent recorded round closed around 2008-01-03.
Valuation (modeled)modeled
Provath models Taligen Therapeutics Inc at approximately $1.4B (range $72M–$5.5B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.61× the median modeled value of Series B Biotechnology companies in 2007–2009 (21 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 18.5 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.4× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 85% of Biotechnology peers (4293 compared).
Modeled value ranks above 92% of those peers.
Closest niche peers: Ion Torrent Systems Inc, PhotoThera Inc, Atritech Inc, Barosense Inc, Palyon Medical Corp.
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.